Fig. 1.

Transforming growth factor-β (TGF-β) expression and Smad2/3 phosphorylation. A: expression of TGF-β is increased in obstructed kidneys (gray bars) compared with contralateral, nonobstructed kidneys (open bars). This ∼4-fold increase is not affected by treatment with imatinib (IM or I) or rapamycin (Rapa or R) alone or in combination at 2 different dosages (n = 6 each). B: in obstructed kidneys smad2/3 phosphorylation is increased compared with nonobstructed kidneys. Smad2/3 phosphorylation is not changed by treatment with imatinib or rapamycin. C: quantitative depiction of pSmad2/3 in control (open bars) and obstructed kidneys (gray bars) in each of the 5 treatment groups (n = 4 each).